Download - Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Transcript
Page 1: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Proactive Investors

Forum

25th June 2009

Page 2: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Disclaimer

This presentation has been organised by Sinclair Pharma plc (the Company) in order to provide general information on the Company. This material has been prepared solely by the Company and is (i) for your private information, and the Company is not soliciting any action based upon it; (ii) not to be construed as an offer to sell or a solicitation of an offer to buy any security and (iii) based upon information that the Company considers reliable. The Company does not represent that the information contained in this material is accurate or complete, and it should not be relied upon as such. No representation, warranty or undertaking, express or implied, is or will be made with respect to the fairness, accuracy or completeness of any of the information or statement of opinion or expectation contained herein or stated in the presentation or any other such information nor shall you be entitled to rely upon it. In furnishing you with this information no obligation is undertaken to provide you with any further information, to update this information nor any other information nor to correct any information contained herein orany omission therefrom.

The Company's securities have not been registered under the U.S. Securities Act of 1933 (as amended), and may not be offered or The Company's securities have not been registered under the U.S. Securities Act of 1933 (as amended), and may not be offered or sold in the United States or to U.S. persons unless they have been registered under such Act, or except in compliance with anexemption from the registration requirements of such Act.

No part of this material may be (i) copied, photocopied, or duplicated in any form, by any means, or (ii) redistributed, published, or disclosed by recipients to any other person, in each case without the Company's prior written consent. This material is only being provided to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 or any order made thereunder or to other persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 or who are otherwise permitted by law to receive it.

In relation to information about the price at which securities in the Company have been bought or sold in the past, note that past performance cannot be relied upon as a guide to future performance. In addition, the occurrence of some of the events described in this document and the presentation that will be made, and the achievement of the intended results, are subject to the future occurrence of many events, some or all of which are not predictable or within the Company's control; therefore, actual results may differ materially from those anticipated in any forward looking statements. The Company disclaims any obligation to update these forward looking statements.

Page 3: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

� Overview

� Product Portfolio

� Globalisation

� Pipeline

� Financial Overview

Agenda

� Financial Overview

� Operational focus

� Milestones

� Investment Summary

� Appendix

1

Page 4: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Sinclair Pharma is a pan European

specialty pharma company with

global reach, providing solutions to

treat

dermatological, oral care and

Introduction

Revenue and Profit since IPO

25

30

35

dermatological, oral care and

gynecological diseases

through advanced surface technology

and innovative delivery system.

Sinclair Pharma is listed on LSE and Euronext

Products registered in EU & US

Products launched in over 40 countries

0

5

10

15

20

2004 2005 2006 2007 2008

FY

£m

Revenue

GP

Page 5: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Our Products

� Patented*

� Clear USP’s

� Substantial Markets

� Market need

� Commercially Viable

19

*Patents owned by SPH

Page 6: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

dermatology oral health non-core

Product Portfolio

Sebclair Atopiclair

B.Derm &

B.Lift

Aloclair

Range

Decapinol

Range SST T-Go Herpclair Sinlice

20

Page 7: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Dermatology

In dermatology, Sinclair provides

specific solutions

to dermatologists and pharmacists

for patients with skin damage and

skin injuries

Three product groups:

•Prescription

•OTC

•Dermo-cosmetics

Built on patented technologies

through its own operations in France,

Italy and Spain

and through its global network of

marketing partners

In 2012, the dermatological market

will generate $19.4bn with a 3%

CAGR from 2006 to 2012

Dermo-cosmetics are growing:

estimated market size of $6.9bn

Page 8: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Product Focus:Dermo-cosmetics

Indication Corrective Dermatology: Anti-ageing, Acne

Competitive

positioning

Efficacious products supported by scientific data

Target audience Dermatologists /Pharmacists/ consumers

22

Page 9: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Product Focus :

Atopiclair

Indication Atopic dermatitis (eczema)

Competitive

positioning

Proven efficacy and safety: steroid-

free, TIM-free, ‘steroid-sparing

Target

audience

Dermatologists, Paediatricians

Registered EU, US

Atopic dermatitis/eczema:

•one of most common skin conditions

•50% of cases identified in infants under 12

months1

•15-24% school aged children2

•2-10% adults3

•8th most common disease in under 25s4

1. C Ellis et al. International Consensus on Atopic Dermatitis II (ICCAS II) br J Dermatol 2003; 148 (supp 63): 3-10

2. Yura et al, Br J Dermatol 2001; 145 (6) 966-73/ Tay et al Br J Dermatol 2002; 146 (1): 101-6 / Mortz. Br J Dermatol 2001; 144 (3) 523-32

3. Verboom et al Br J Dermatol 2002; 147 (4) 716-24

4. Frequence of atopic dermatitis. Postgraduate medicine June 2001 p119

Page 10: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Corrective Dermatology:SPHR913

� Topical anti-ageing product containing Telmesteine developed by Sinclair

� Multiple mode of action to reduce the appearance of fine lines and wrinkles

� Reduce Collagen destruction

� Reduce Elastin destruction

� Inhibition of hyaluronidase: maintains skin’s natural hydration� Inhibition of hyaluronidase: maintains skin’s natural hydration

Page 11: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

� N=30, 6 week study

� Objective results supported by positive results for

subjective criteria

� Objective outcomes:

� Skin elasticity

� Increased elastic component

Before

SPHR913:Initial Clinical Study

� Increased elastic component

� Decreased plastic component

� Profilometry

� Skin compactness, smoothness, roughness

� Decreased micro-roughness

� Tensor “lifting effect”

� Subjective outcomes:

� Acceptability

� Efficacy

After

Page 12: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

In oral care, Sinclair provides

oral care solutions

for mouth & gum diseases

to specialists and pharmacists

Oral Health

� Two flagship brands:

�Decapinol®, for gum disease (gingivitis) and plaque

�Aloclair® for mouth ulcers

� Both approved in the US & EU to specialists and pharmacists

marketed

through its global network of

marketing partners

� Both approved in the US & EU and in some additional territories

Page 13: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Product Focus: Aloclair Plus

Indication: Mouth ulcers

Mode of Action:

29

Before: exposed nerve endings over-stimulated After: exposed nerve endings protected from

over-stimulation

Page 14: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Product Focus: Decapinol

Indication Gingivitis (gum disease), dental

plaque

Competitive

positioning

First new product class in gingivitis

for decades. ‘Intelligent’ mode of

action, targeting ‘bad’ bacteria. Lack

of tooth staining.

Target

audience

Dentists

Registration EU, US

Next Steps: � Expand geographic coverage

� US launch

� Further toothpaste and line

extension launches

Page 15: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

In gynaecology, Sinclair is developing

gynaecological solutions

for gynaecologists and pharmacists

to be marketed

Gynaecology

to be marketed

through its global network of marketing

partners,

outside Americas

Page 16: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

New Market EntriesNew Market Entries

2

Page 17: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

TGo: Teething

symptoms

SINLICE: Head lice HERPCLAIR: Herpes simplex

cold sores30% of population infected

with HSV

Competitive

positioning:

barrier-based pain

relief aimed at

paediatricians and

Novel, safe and

effective

treatment to kill

reduces the

symptoms and

accelerates the

New Market Entries

paediatricians and

consumers

treatment to kill

head lice and their

eggs

accelerates the

healing process

Next Steps: �Establish partners

�Expand geographic coverage

Page 18: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Global Reach

18

Page 19: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Marketing Partner Network

High quality, targeted alliances

Page 20: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Decapinol

Papulex

B.Lift &

B.DermSinlice

Herpclair

T-Go

Sebclair

Geographical

Expansion

Commercialisation Drivers

Fadiamone

Optys

Effadiane

Keren

AloclairBio-

Taches

Gen-

Ongles

Tridesonit

Affina-

Lift

Atopiclair

28

Page 21: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Financial OverviewFinancial Overview

2

Page 22: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Revenue Growth

Revenue growth since IPO (UK £m)

23.2

30.3

2007

2008

2.6

7.0

11.6

23.2

2004

2005

2006

2007

7

Page 23: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Financial Highlights H1 09

�Total revenues up 56% to £16.2m £10.4m

�Gross profit up 77% to £11.8m £6.7m

�Operating profit of £4.1m (£0.9m)

H1 08

�Operating profit of £4.1m (£0.9m)

�EBITDA profit of £2.2m (£1.6m)

�Earnings per share of 4.0p (1.1p)

�Cash balance on 31st December 2008 of £2.4m

6

Page 24: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

� Address current marketplace challenges

� Continue organic growth

� Build sustainable brands

� Pursue M&A opportunities

Operational Focus

� Pursue M&A opportunities

31

Page 25: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

FY2010 Milestones

� Sebclair US Launch

� Decapinol US launch � Decapinol US launch

� Approval of Decapinol in Japan

Page 26: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

� Robust business model

� Profitable

� Experienced management team

Investment Summary

� Experienced management team

� Innovative portfolio

� Rich pipeline

32

Page 27: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

AppendixAppendix

Page 28: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Generate substantial and sustainable profits

Become a world class specialty pharma companyVision

Strategic Objective

Core

•Reinforce internal sales & marketing capabilities

•Increase sales of existing products

Strategy

•Increase organic growth

•Build & leverage Brand Equity

•Expand into new therapeutic areas

•Utilise existing technology

Identify & manage issues and challenges -•Secure cash flow

-Conserve cash

- Build cash cushion

•Monitor financial strength of partners

•Secure new partners & alternative suppliers

•Effective Contingency planning

Core

Tactics

Long Term

Focus

Short Term

Focus

•Increase sales of existing products

•New Product Launches

•Opportunistic M&A

•Product acquisition

5

Page 29: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Development of Sinclair

Phase 1: Building a portfolio

� Acquired and developed technologies

� Sold products only through partners

2000 Acquisition of Salix Pharma (Swedish) bringing SST for

xerostomia. Consideration £120k.

2001 Acquisition of ProPharma (Italian), bringing dermatology

range including Atopiclair. Consideration £3.6m.

2002 Acquisition of Biosurface (Swedish), bringing Decapinol for

gingivitis. Consideration £10m.

Phase 2: Building a commercial presence

� Acquisition of European marketing

2003 IPO on AIM, raising £8.9m

� Acquisition of European marketing

operations

� Continue portfolio growth - acquire

and develop technologies

2004

2005 Acquisition of Euroderm, establishing sales presence in

Italy. Consideration £4m.

2006 Acquisition of CS Dermatologie, establishing sales presence

in France, Spain, Portugal. Consideration £38m.

Acquisition of Ashbourne (British), establishing sales

presence in UK. Consideration £1.2m.

Phase 3: Building critical mass

Goal: Become a sustainably profitable,

international pharma company with an

integrated specialty salesforce

2007 H2: first profitable half year since IPO

2008

2009

FY08: first profitable full year since IPO

H1: first profitable H1 at EBITDA level since IPO

4

Page 30: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

PipelinePipeline

Driving organic growth

through portfolio expansion

29

Page 31: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Therapeutic

areas

FY2010

(Jul09–Jun10)

FY2011

(Jul10–Jun11)

FY20102

(Jul11–Jun12)

Market Opportunity

MAS011

1st & 2nd degree burns

Dermatology Under development Target filing EU, USA $ 1.9bn *****

SPHD600

Psoriasis

Dermatology Under development Target filing EU, USA 18 m patients ww (7.7 only in

USA)

$ 921 m ($ 764 topical)

SPHR910-1-2-3-4-5-6-7-8

anti-aging

Dermatology Target filing EU Target filing USA $ 3.6bn only in USA

($ 855m Hyaluronic acid based)

SPHD652

Dermatitis

Dermatology Target filing EU Target filing USA 46m patients** (17m only in

USA)

Pipeline:New Products

Dermatitis USA)

SPHD 654

Dry skin

Dermatology Target filing EU, USA

SPHD 653

Dry skin

Dermatology Target filing EU, USA

MAS054D

Dry skin

Dermatology Target filing EU, USA

Page 32: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Therapeutic areas FY2010

(Jul09–Jun10)

FY2011

(Jul10–Jun11)

FY20102

(Jul11–Jun12)

Market Opportunity

SPHD427

Acne

Dermatology Under Development Target filing EU 150m patients*(60m only in

USA)

$ 2.6bn ($1.8 topical and $0.8

oral treatments)

SPHD428

Acne & Sunscreen

Dermatology Under Development Target filing EU 150m patients*(60m only in

USA)

$ 2.6bn ($1.8 topical and $0.8

oral treatments)

SPHD487

Hyperpigmentation

Dermatology Under Development Target filing EU Target Filing USA

Pipeline:Line Extensions

SPHD785

Hyperpigmentation

Dermatology Under Development Target filing EU Target Filing USA

SPHD752

Anti-ageing

Dermatology Under Development Target filing EU $ 3.6bn only in USA

($ 855m Hyaluronic acid based)

Page 33: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Therapeutic

Areas

FY2010

(Jul09–Jun10)

FY2011

(Jul10–Jun11)

FY2012

(Jul11–Jun12)

BMG1601

Iron deficiency

OBGYN Target filing EU, US

BMG1301

Breast Tension

OBGYN Target filing US

Registered EU

BMG1001

Genital Warts

OBGYN In development In development Target filing EU, USA

BMG0905

Vaginal lubricant

OBGYN In development Target filing EU, USA

Pipeline:Gynaecology

Vaginal lubricant

BMG0501

Interstitial Cystitis

OBGYN In development In development Target filing EU, USA

SPHG820

BRAND N.A.

Bi-Phasic cannula

OBGYN In development Target filing EU, USA

SPHG800

Vulvitis cream

OBGYN Target filing EU Target filing USA

Page 34: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Therapeutic areas FY2008

(Jul07–Jun08)

FY2009

(Jul08–Jun09)

FY2010

(Jul09–Jun10)

Market Opportunity

SPHR972

Atopic dermatitis

Dermatology Under

development

SPHD440

Rosacea

Dermatology Under

development

44m patients ww (17m

only USA)

SPHO206

Lichen Planus

Oral Health Under

development

1-2% of general

population****

SPHD770 Dermatology Under

Pipeline:Early Stage

SPHD770

Skin infection

Dermatology Under

development

SPHD420

Acne

Dermatology Under

development

150m patients*(60m

only in USA)

$ 2.6bn ($1.8 topical and

$0.8 oral treatments)

Page 35: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Additional Clinical SupportAdditional Clinical Support

29

Page 36: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Product Focus:Fadiamone

� Fadiamone: for ageing skin

� Designed to stimulate collagen production

60

80

100

120

Effects of vehicle and

Fadiamone on the

quantity of collagen

+256%In vivo data :

•Statistically significant

increase in collagen

content in Fadiamone

0

20

40

60

Vehicle Fadiamone

Collagenic hydroxyproline

(micrograms/sample)

quantity of collagen

in the skincontent in Fadiamone

groups compared to

vehicle (p<0.01)

Page 37: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Clinical Data:Abramovits et al (2006)

Mean itch score

4050607080

itch

scor

e (1

00m

m V

AS

)

Atopiclair

•Design: N=218 adults, 50 day study, multicentre RCT

Mean EASI scores

4567

EA

SI

scor

e

Atopiclair

010203040

Baelin

e/da

y 1

Day 8

Day 22

Day 36

Day 50

itch

scor

e (1

00m

m V

AS

)

emollient

•Abramovits et al. “A multicenter, randomised, vehicle-controlled clinical study to examine the efficacy and safety of

Atopiclair in the management of mild to moderate atopic dermatitis in adults.” J Drugs Dermatol 2006; 5(3): 223-244

01234

Baelin

e/da

y 1

Day 8

Day 22

Day 36

Day 50

EA

SI

scor

e

emollient

EASI*: Atopiclair significantly more effective

than emollient at all time points (p<0.0001)

Itch: Atopiclair significantly better at all time

points (p<0.0001). Rapid reduction on VAS

scale

* EASI (Eczema Area and Severity Index)

Page 38: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

� Multicentre, double-blind, US study in children and infants

� n=142, 43 days, Atopiclair vs emollient control

� Improved itch

� Steroid-sparing p<0.001

� Highly significant treatment success p<0.001

Clinical Data:Boguniewicz M et al (2008)

Boguniewicz M, Zeichner JA, Eichenfield LF, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and

children: A multicenter, randomized, vehicle-controlled study. J Pediatr 2008;152:854-859.

Page 39: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

� Study to evaluate effect of product on wrinkles, skin luminosity and skin thickness

� 12 subjects: 2 month study

� Skin Hydration: statistically significant increase (22.1%) from baseline (p=0.01)

� Skin Elasticity: statistically significant decrease in deformation (22.2%) from baseline (p<0.01)

� Overall elasticity: statistically significant increase (14.8%) (p<0.05)

� Skin thickness: statistically significant increase (ultrasound) (4.2%) p<0.05

SPHR913: Further Clinical Data

� Skin thickness: statistically significant increase (ultrasound) (4.2%) p<0.05

� Skin roughness: highly statistically significant decrease in maximum roughness (-13.8%) (p<0.01)

Page 40: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Grahame Cook ACA

Non-executive Chairman

Dr Michael Flynn

Chief Executive Officer

Jerry Randall ACA

Chief Financial Officer

Board of Directors

Non-executive Chairman Chief Executive Officer Chief Financial Officer

Penny Freer Jean-Charles Tschudin

Non-executive Director Non-executive Director

Page 41: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

Christophe Foucher Marco Mastrodonato Paul Phull Alan Olby

Senior Management

Christophe Foucher

Chief Operating Officer

Marco Mastrodonato

Executive Vice President

NPD

Paul Phull

Executive Vice President

International Operations

Alan Olby

Finance Director

Company Secretary

Mike Killeen

Executive Vice President,

North America

Vittorio Cavagnera

Vice President

Manufacturing & Logistics

Mariyam Rawat

Director of Communications

& Investor Relations

Steve Redman

Legal Director

Page 42: Proactive Investors Forum...Atopiclair Indication Atopic dermatitis (eczema) Competitive positioning Proven efficacy and safety: steroid-free, TIM-free, ‘steroid-sparing Target audience

For further information visit our website at http://www.sinclairpharma.com

or email: [email protected]